Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Zimmer Biomet Holdings / Equity Bottom-Up

<ul><li>Zimmer Biomet's first-quarter performance for 2025 showcased gradual growth, amidst an environment of various challenges and strategic changes.</li><li>The company reported a 2.3% increase in constant currency sales, despite having one less selling day in the quarter.</li><li>This growth was largely driven by specific improvements in U.S. Hips sales, which saw an almost 4% increase, and mid-single-digit growth in their S.E.T. segment.</li></ul>

Zimmer Biomet's first-quarter performance for 2025 showcased gradual growth, amidst an environment of various challenges and strategic changes.The company reported a 2.3% increase in constant currency sales, despite having one less selling day in the quarter.This growth was largely driven by specific improvements in U.S. Hips sales, which saw an almost 4% increase, and mid-single-digit growth in their S.E.T. segment.

Zimmer Biomet: Recent Advancements in Robotic & Surgical Technology Look Promising!

<ul><li>Zimmer Biomet reported its fourth-quarter and full-year 2024 financial results, reflecting a complex but strategically advancing fiscal year.</li><li>The company achieved a constant currency revenue growth of nearly 5%, marking its twelfth consecutive quarter of at least mid-single-digit growth.</li><li>This robust performance, despite challenges like ERP implementation setbacks, underscores Zimmer Biomet's resilience amidst a volatile market landscape.</li></ul>

Zimmer Biomet reported its fourth-quarter and full-year 2024 financial results, reflecting a complex but strategically advancing fiscal year.The company achieved a constant currency revenue growth of nearly 5%, marking its twelfth consecutive quarter of at least mid-single-digit growth.This robust performance, despite challenges like ERP implementation setbacks, underscores Zimmer Biomet's resilience amidst a volatile market landscape.

Zimmer Biomet: The 6 Most Significant Forces Steering Its Performance into 2025 & Beyond!

<ul><li>Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges.</li><li>The company, a major player in the medical devices sector, particularly in orthopedics, navigated through intricate dynamics, including an ERP implementation issue that significantly impacted its operations.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges.The company, a major player in the medical devices sector, particularly in orthopedics, navigated through intricate dynamics, including an ERP implementation issue that significantly impacted its operations.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Zimmer Biomet Holdings: An Analysis Of Its Enhanced Product Portfolio

<ul><li>Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic advancements, though it faced specific challenges during the period.</li><li>The company reported a year-over-year revenue growth of 5.6% on a constant currency basis for the second quarter of 2024.</li><li>This marks Zimmer Biomet's tenth consecutive quarter of mid-single-digit or higher growth.</li></ul>

Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic advancements, though it faced specific challenges during the period.The company reported a year-over-year revenue growth of 5.6% on a constant currency basis for the second quarter of 2024.This marks Zimmer Biomet's tenth consecutive quarter of mid-single-digit or higher growth.

Zimmer Biomet Holdings Inc.: Enhanced Focus on Robotic & Cementless Technologies & Global Expansion! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. The dust has yet to settle, but the selloff has been largely contained to AI-linked stocks.</li>
<li>The rest of the market did not seem to care; the equal-weighted S&amp;P 500 was roughly flat yesterday.</li>
<li>Additionally, market dynamics remain healthy. Bottom line: as long as the S&amp;P 500 remains above 5600-5670, our long-term outlook remains bullish.</li>
</ul>


DeepSeek appears to have turned the chatbot market upside-down, putting pressure on AI-linked stocks. The dust has yet to settle, but the selloff has been largely contained to AI-linked stocks.
The rest of the market did not seem to care; the equal-weighted S&amp;P 500 was roughly flat yesterday.
Additionally, market dynamics remain healthy. Bottom line: as long as the S&amp;P 500 remains above 5600-5670, our long-term outlook remains bullish.


S&P 500 Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness

United States

Zimmer Biomet Holdings, Inc. designs, develops, manufactures, and markets medical equipment. The Company offers orthopedic and dental reconstructive implants, spinal implants, trauma products, and related surgical products. Zimmer Biomet Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Zimmer Biomet Holdings (ZBH US)

Zimmer Biomet: Recent Advancements in Robotic & Surgical Technology Look Promising!

Zimmer Biomet's first-quarter performance for 2025 showcased gradual growth, amidst an environment of various challenges and strategic...

Baptista Research

Zimmer Biomet: The 6 Most Significant Forces Steering Its Performance into 2025 & Beyond!

Zimmer Biomet reported its fourth-quarter and full-year 2024 financial results, reflecting a complex but strategically advancing fiscal year. The...

Baptista Research

Zimmer Biomet Holdings: An Analysis Of Its Enhanced Product Portfolio

Zimmer Biomet recently presented its third-quarter 2024 results, underscoring several key areas of progress and challenges. The company, a major...

Baptista Research

Zimmer Biomet Holdings Inc.: Enhanced Focus on Robotic & Cementless Technologies & Global Expansion! - Major Drivers

Zimmer Biomet Holdings, Inc.'s most recent quarterly performance reflects a steadied progress in its growth trajectory and continuous strategic...

Baptista Research

S&P 500 Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness

$SPX Testing Prior Breakout Level; Market Dynamics Remain Healthy Despite AI-Linked Weakness; $DXY, Treasury yields, and crude oil near-term tops...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)